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Perfluorooctanoic acid (PFOA) is a fully 
fluorinated eight-carbon perfluoroalkyl acid 
(PFAA) with a carboxylic acid functional 
group. As with other PFAAs, PFOA is used 
in the production of fluoro  chemicals, which 
have extensive commercial applications 
(Prevedouros et al. 2006). PFOA is also a 
final breakdown product of certain fluoro-
chemicals and resists degradation in the 
ambient environ  ment by biota or physical 
processes (Martin et al. 2005). The ubiquity 
of fluoro  chemicals in the market  place, com-
bined with the persistence of PFOA in the 
environ  ment, may explain current widespread 
PFOA contamination of humans and wildlife 
(Giesy and Kannan 2002; Harada et al. 2004; 
Martin et al. 2004).
The average nonoccupationally exposed 
American exhibits measurable serum PFOA, 
varying between a mean concentration 
of 3.9 ng/mL among participants in the 
2003–2004 National Health and Nutrition 
Examination Survey (Calafat et al. 2007) 
and 2.2 ng/mL in 2005 among a smaller 
group of Red Cross blood donors (Olsen 
et al. 2007). Occupational exposure can raise 
serum concentrations more than 200 times 
this approxi  mate range (Emmett et al. 2006). 
In the Little Hocking district of Ohio and 
West Virginia where the municipal drinking-
water supply was contaminated with PFOA 
at 3.55 ng/mL (ppb) by nearby production 
plants, mean human serum concentrations 
were 423 ng/mL (Emmett et al. 2006). Thus, 
non  occupationally exposed Americans may 
receive substantial unforeseen exposures to 
PFOA. It is not known, however, whether 
adverse adult health effects could result from 
these chronic, low-level exposures beginning 
in early life. This is of particular interest with 
respect to develop  ment, because the poten-
tial toxicity of PFOA in humans remains 
uncharac  terized.
Mouse studies have demonstrated the 
capacity for gestational PFOA exposure to 
yield develop  mental toxicity (Lau et al. 2004, 
2006; Wolf et al. 2007). The mammary 
gland, specifically, has proven to be a sensi-
tive tissue with respect to the develop  mental 
end points addressed, including functional 
lactation, milk protein gene expression, and 
developing neo  natal and peri  pubertal struc-
tures (White et al. 2007, 2009; Yang et al. 
2009; Zhao et al. 2010). In outbred CD-1 
mice, treatment with 3 mg/kg PFOA during 
pregnancy resulted in delayed gland develop-
ment among offspring, which persisted into 
adulthood, even among offspring with lac-
tational exposures only (White et al. 2009). 
Another laboratory examined simi  lar dose 
ranges using peri  pubertal exposures [post-
natal days (PNDs) 21–50] in two inbred 
mouse strains, C57Bl/6 and Balb/C. The 
researchers observed a similar inhibi  tory 
effect on mammary gland develop  ment in 
Balb/C mice (Yang et al. 2009), whereas 
C57Bl/6 females exhibited stimulatory or 
inhibitory effects depending on dose (Yang 
et al. 2009; Zhao et al. 2010). These observa-
tions illustrate the influence not only of dose 
but also of exposure timing and genetic back-
ground. They confirm that the mammary 
gland represents a sensitive tissue in multiple 
mouse strains.
To understand the extended consequences 
of altered mammary gland develop  ment, we 
performed a multi  generational study examin-
ing the ability of the develop  mentally exposed 
females to provide lactational support for 
their litters. To address the human relevance 
of the route, dose, and duration of expo-
sures employed in our studies, we included a 
chronic low-dose exposure.
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Ba c k g r o u n d: Prenatal exposure to perfluorooctanoic acid (PFOA), a ubiquitous industrial 
  surfactant, has been reported to delay mammary gland develop  ment in female mouse offspring (F1) 
and the treated lactating dam (P0) after gestational treatments at 3 and 5 mg PFOA/kg/day.
oB j e c t i v e: We investigated the consequences of gestational and chronic PFOA exposure on F1 lac-
tational function and subsequent develop  ment of F2 offspring.
Me t h o d s : We treated P0 dams with 0, 1, or 5 mg PFOA/kg/day on gestation days 1–17. In addi-
tion, a second group of P0 dams treated with 0 or 1 mg/kg/day during gestation and their F1 and 
F2 offspring received continuous PFOA exposure (5 ppb) in drinking water. Resulting adult F1 
females were bred to generate F2 offspring, whose develop  ment was monitored over post  natal 
days (PNDs) 1–63. F1 gland function was assessed on PND10 by timed-lactation experiments. 
Mammary tissue was isolated from P0, F1, and F2 females throughout the study and histologically 
assessed for age-appropriate develop  ment.
re s u l t s: PFOA-exposed F1 dams exhibited diminished lactational morphology, although F1 
maternal behavior and F2 offspring body weights were not significantly affected by P0 treatment. In 
addition to reduced gland develop  ment in F1 females under all exposures, F2 females with chronic 
low-dose drinking-water exposures exhibited visibly slowed mammary gland differentiation from 
weaning onward. F2 females derived from 5 mg/kg PFOA-treated P0 dams displayed gland mor-
phology similar to F2 chronic water exposure groups on PNDs 22–63.
co n c l u s i o n s: Gestational PFOA exposure induced delays in mammary gland develop  ment and/or 
lactational differentiation across three generations. Chronic, low-dose PFOA exposure in drinking 
water was also sufficient to alter mammary morphological develop  ment in mice, at concentrations 
approximating those found in contaminated human water supplies.
key w o r d s : delayed develop  ment, fetal origins of adult disease, lactation, mammary gland, 
multi  generational, perfluoro  octanoic acid (PFOA). Environ Health Perspect 119:1070–1076 
(2011).  doi:10.1289/ehp.1002741 [Online 18 April 2011]PFOA and mouse mammary effects in multiple generations
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Materials and Methods
Animals. Timed-pregnant CD-1 mice were 
purchased from Charles River Laboratories 
(Raleigh, NC). Sperm-positive females [gesta-
tional day (GD) 0] were weighed upon arrival 
at the U.S. Environmental Protecion Agency 
(EPA). Animals were housed individually 
in poly  propylene cages, and received food 
(LabDiet 5001; PMI Nutrition International 
LLC, Brentwood, MO) and tap water ad libi-
tum in polyethylene water bottles sealed with 
rubber stoppers and stainless-steel sipper 
tubes, as specified by White et al. (2009). 
Animal protocols were approved by the U.S. 
EPA’s Institutional Animal Care and Use 
Committee. Animals were treated humanely 
and with regard for alleviation of suffering.
Dosing solutions. PFOA (ammonium 
perfluoro  octanoate; > 98% pure) was pur-
chased from Fluka Chemical (Steinheim, 
Switzerland). PFOA was dissolved by agi-
tation in deionized water at concentrations 
of 0.1 and 0.5 mg/mL (for 1 and 5 mg/kg 
doses, respectively) and prepared fresh daily, 
immediately before administration. PFOA-
containing drinking water was prepared 
similarly, by serial dilution to a final concen-
tration of 5 ng/mL (ppb). Drinking water was 
prepared fresh weekly, and cage bottles were 
refilled weekly after rinsing.
Study design. A study timeline is 
shown in Supplemental Material, Figure 1 
(doi:10.1289/ehp.1002741). Timed preg-
nant P0 (parental generation) dams were 
randomly distributed among five treatment 
groups. Three groups were treated once daily 
by oral gavage on GDs 1–17 (desig  nated 
“gestational”) with PFOA doses of 0 (con-
trol; n = 10), 1 (n = 12), or 5 mg/kg body 
weight (n = 11). The remaining two groups 
received PFOA at 0 (n = 7) or 1 mg/kg 
(n = 10) as described above, but also received 
PFOA (5 ppb) in their drinking water (desig-
nated “chronic”) to approxi  mate the 3.55 ppb 
PFOA present in the contaminated drinking- 
water supply in Little Hocking, Ohio (Emmett 
et al. 2006). These two groups received PFOA-
containing drinking water throughout gesta-
tion (starting on GD7) and for the duration 
of the study, as did subsequent F1 and F2 off-
spring (except during F1 breeding and early 
gestation, to avoid exposing control males). 
Weekly water consumption was calculated 
per cage by weighing bottles when filled and 
again at the end of the week; the differential 
reflected consumption.
P0 dams were weighed daily through-
out gestation. On PND1, F1 litters were 
weighed and sexed. F1 neonates were pooled 
and randomly redistributed to dams of their 
respective treatment groups, consistent with 
previous studies (Lau et al. 2006; White et al. 
2009), equalizing litters to 12–13 neo  nates, 
with simi  lar sex representation. Litters were 
moni  tored and weighed on PND10. On 
PND22, F1 offspring were weaned, and dams 
and 1–2 female offspring/litter were weighed 
and necropsied (n = 5–7 litters/treatment   
group). A subset of F1 females were main-
tained into adulthood and weighed and 
necropsied at PND42 and PND63 (n = 6–8/
treatment group).
Remaining adult F1 females were bred to 
age-matched control F1 males at 7–8 weeks 
of age, on the night of proestrus (determined 
by vaginal cytology). Breeding pairs remained 
together overnight only, and plug-positive 
females (GD0) were housed individually and 
monitored over gestation (n = 7–10 F1 dams/
treatment group). On PND1, F2 neo  nates 
were weighed and sexed. F2 litters were equal-
ized to 10 neonates for the lactational challenge 
experiment. F1 dams and 3 female offspring 
per F2 litter were sacrificed on either PND10 
or PND22. The remaining F2 females were 
weaned and necropsied on either PND42 or 
PND63 (n = 4–8/treatment group).
The lactational challenge experiment was 
performed with F1 dams and their F2 litters 
on PND10, the peak of lactation. Dams were 
separated from offspring for 3 hr and then 
returned to their litters and allowed to nurse 
for 30 min. The time between reunion and 
initiation to nurse (arched back position over 
the litter) was recorded to the nearest second, 
as was the weight of the 10-pup litter before 
and after precisely 30 min of nursing, in order 
to estimate the volume of milk produced dur-
ing the nursing period. Dams were euthanized 
and necropsied immediately after nursing.
Necropsy. All animals were terminated by 
decapitation; trunk blood was collected and 
serum was isolated and stored at –80°C in 
snap-top poly  propylene tubes for PFOA analy-
sis. Uteri were dissected from P0 and F1 dams, 
and implantation sites were visually identified 
by light macroscope (Leica WILD M420 mac-
roscope; Leica, Wetzlar, Germany) to assess 
post  implantation loss per dam. Mammary 
glands were collected as described below.
Mammary gland preparation. Mammary 
glands were removed from P0 and F1 dams 
on PND10 (F1 dams only) and PND22 
(n = 4–12/treatment group) because these 
times represent peak lactational output and 
weaning, respectively. In F1 and F2 offspring, 
a set of fourth and ﬁfth glands was removed 
from the skin and ﬂattened onto glass slides. 
Whole-mounts were ﬁxed in Carnoy’s solu-
tion, stained in carmine alum, and then dehy-
drated and cleared in xylene, as previously 
described (Fenton et al. 2002). From dams 
only, a portion of the contra  lateral mam-
mary gland was removed, placed in a histol-
ogy cassette, ﬁxed in 10% neutral buffered 
formalin for 48 hr, and stored in 70% etha-
nol. These tissues were embedded in parafﬁn, 
and 5 μm sections were prepared and stained 
with hematoxylin and eosin (H&E). Whole-
mounts and histological sections were visual-
ized by light macroscope.
Mammary gland whole-mounts from 
F1 and F2 female offspring were scored on a 
1–4 subjective, age-appropriate develop  mental 
scale (4 = excellent develop  ment/structure; 
1 = poor develop  ment/structure). The number 
of primary ducts and large secondary ducts, 
lateral side branching, appearance of budding 
from the ductal tree, and longitudinal out-
growth of the epithelia were assessed. Because 
we did not address estrous cycle stage at the 
time of necropsy, we did not include stage-
sensitive morphologi  cal traits in scoring cri-
teria. Slides were separated by score during 
evaluation, compared within a score for con-
sistency, and then recorded. Two individuals, 
blind to treatment, scored glands. Mean scores 
for the various ages and treatment groups were 
calculated and analyzed statistically for treat-
ment and time-related differences.
H&E-stained lactating mammary gland 
sections from P0 and F1 dams were similarly 
scored on a 1–4 subjective scale. A value of 4 
represented well-differentiated, functionally 
lactating tissue charac  terized by extensive epi-
thelium, reduced adiposity, and presence of 
secretory alveoli, consistent with the peak of 
lactation (PND10, as previously described by 
Vorderstrasse et al. 2004). A value of 1 repre-
sented little or diminishing presence of lobulo-
alveoli and extensive involution and regression 
of the tissue, with the presence of apoptotic 
bodies, increasing adiposity, and regressing 
alveoli, as anticipated at weaning (PND22). At 
both time points, dams were euthanized imme-
diately after removal from litters to ensure 
comparable lactational morphology. Mammary 
glands representing the mean score or obser-
vation for each treatment group were photo-
graphed using the described macroscope and 
mounted camera (Photometrics CoolSNAP; 
Roper Scientiﬁc, Inc., Tucson, AZ).
Measurement of PFOA in serum. Serum 
samples from the P0 and F1 dams at PND22 
and from F1 and F2 offspring at PNDs 22, 
42, and 63 were stored frozen in snap-top 
poly  propylene vials until they were shipped 
on dry ice to the Centers for Disease Control 
and Prevention (CDC) laboratory. Serum 
PFOA measurements were performed by the 
CDC using the methodology described in 
detail by White et al. (2009).
Data analysis. Data were evaluated for 
dose effects using mixed-model analysis of vari-
ance in SAS (version 9.1; SAS Institute Inc., 
Cary, NC). For both generations, treatment-
specific mean gestational weight gain was cal-
culated for dams between GD1 and GD17, 
and treatment-specific mean body weights 
were determined for F1 and F2 offspring on 
PNDs 22, 42, and 63. In addition, we calcu-
lated F2 offspring body weight means at PNDs White et al.
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1, 3, 5, 10, 14, and 17, based on whole-litter 
weights (divided by number of pups; litter 
used as the unit of measure before weaning). 
For all three generations, mean mammary 
gland lactational or develop  mental scores were 
calculated. Scores were analyzed using body 
weight at time of collection as a random effect, 
with litter as the unit of meas  ure for neo  natal 
scores. For both P0 and F1 dams, we calcu-
lated mean implant number, percentage of 
postimplantation (pre  natal) loss, and percent-
age of post  natal survival. Differences between 
treatment groups were determined using 
Dunnett’s, Tukey’s, or Student’s t-tests, with 
significance set at p < 0.05 for all comparisons. 
Results
P0 dams and F1 offspring. We found no sig-
nificant effect of PFOA on P0 dam gestational 
weight gain or implant number (Table 1). 
Consistent with previous studies (White et al. 
2007, 2009; Wolf et al. 2007), gestational 
5 mg/kg PFOA significantly reduced the num-
ber of live fetuses, prenatal survival, and post-
natal offspring growth and survival, but similar 
effects were not observed with 1 mg/kg PFOA 
or with drinking-water treatment (Table 1). 
Given these observations in P0 dams—and 
in agreement with the conclusions of prior 
studies (Lau et al. 2006; Wolf et al. 2007)—
maternal toxicity was not responsible for F1 
develop  mental deficits seen at low exposures.
As evidenced by significantly elevated 
histological scores at PND22, normal wean-
ing-induced mammary involution was com-
promised among all PFOA-treated P0 dams, 
including those with only low-dose exposures 
via drinking water (Table 1). In contrast with 
the extensive gland regression observed in con-
trol dams at weaning, glands in PFOA-treated 
dams at PND22 demon  strated structural simi-
larity to normal dam mammary tissue at or 
near the peak of lactation at PND10, includ-
ing the presence of functional lobulo  alveolar 
units (data not shown). This observation was 
consistent with our previous finding that ges-
tational PFOA exposure delays lactational dif-
ferentiation and eventual involution in the 
exposed dam (White et al. 2007), but here we 
Table 1. P0 maternal indices (mean ± SE; n = 7–11).
Maternal index Control
Control + 
5 ppb PFOA 1 mg/kg
1 mg/kg + 
5 ppb PFOA 5 mg/kg
Gestational weight gain (g) 24.8 ± 1.2 25.0 ± 1.2 26.0 ± 1.2 27.0 ± 1.2 27.7 ± 1.2
Implants (no. per live litter) 12.8 ± 0.5 12.7 ± 0.4 13.5 ± 0.7 14.0 ± 0.4 13.7 ± 0.6
Live fetuses (no. per live litter) 12.0 ± 0.5 11.7 ± 0.4 12.9 ± 0.7 13.3 ± 0.5 10.0 ± 0.8*
Prenatal loss (% per live litter) 6.1 ± 1.8 7.8 ± 1.7 4.5 ± 1.7 5.1 ± 1.6 25.8 ± 5.6*
Postnatal survival (% per live litter) 96.1 ± 1.3 100 ± 0.0* 98.8 ± 0.8 89.5 ± 6.4 72.7 ± 5.8*
Mammary gland score (1–4 scale), 
PND22
2.4 ± 0.2 3.4 ± 0.1* 3.0 ± 0.2* 3.2 ± 0.2* 3.9 ± 0.1*
*p < 0.05 compared with control. 
Table 2. F1 developmental indices (mean ± SE; n = 4–10).
Developmental index Control
Control + 
5 ppb PFOA 1 mg/kg
1 mg/kg + 
5 ppb PFOA 5 mg/kg
Body weight (g)
PND22 12.70 ± 0.69 12.69 ± 0.87 13.40 ± 0.49 13.20 ± 0.37 11.28 ± 0.45
PND42 25.65 ± 0.43 24.28 ± 0.57 24.24 ± 0.74 24.90 ± 0.62 22.28 ± 0.60*
PND63 28.77 ± 0.96 26.23 ± 1.81 29.93 ± 0.97 26.35 ± 0.84# 27.88 ± 1.25
Liver:body weight ratio (×100%)
PND22 5.56 ± 0.16 5.29 ± 0.13 6.35 ± 0.08* 5.96 ± 0.12 7.81 ± 0.34*
PND42 5.19 ± 0.24 5.75 ± 0.22 5.32 ± 0.10 5.26 ± 0.13 5.79 ± 0.09*
PND63 4.85 ± 0.17 4.99 ± 0.12 4.97 ± 0.13 4.82 ± 0.15 5.24 ± 0.28
Body weight excluding liver weight (g)
PND22 11.99 ± 0.64 11.16 ± 0.86 12.55 ± 0.46 12.55 ± 0.36 10.39 ± 0.39
PND42 24.32 ± 0.44 22.89 ± 0.54 22.94 ± 0.69 23.59 ± 0.58 20.99 ± 0.57*
PND63 27.38 ± 0.94 24.92 ± 1.74 28.49 ± 1.12 24.43 ± 1.09 26.43 ± 1.24
Mammary gland score (1–4 scale)
PND22 3.8 ± 0.1 2.5 ± 0.2* 2.3 ± 0.2* 2.2 ± 0.1* 1.6 ± 0.1*
PND42 3.8 ± 0.1 3.3 ± 0.2* 2.6 ± 0.4* 2.2 ± 0.3* 2.3 ± 0.2*
PND63 3.8 ± 0.2 2.6 ± 0.4* 2.9 ± 0.2* 2.0 ± 0.3*# 2.2 ± 0.2*
*p < 0.05 compared with control. #p < 0.05 compared with 1 mg/kg. 
Figure 1. F1 female mammary gland development. Mammary whole-mounts illustrate morphology representative of treatment groups at PNDs 22, 42, and 63 
(n = 6–7 females/treatment/age). Bars = 1,000 μm for PND22 and 2,000 μm for PND42 and PND63. 
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also observed the effect with exposure to 5 ppb 
PFOA in drinking water for a total of 34 days 
[for dose estimates, see Supplemental Material, 
Table 1 (doi:10.1289/ehp.1002741)].
F1 offspring body weights and adjusted 
body weights (body weight less liver weight) 
between PND22 and PND63 were not 
consistently associated with PFOA treat-
ment (Table 2). Liver:body weight ratios at 
PND22 were significantly elevated among F1 
females exposed to 1 or 5 mg/kg, consistent 
with hepatomegaly. At PND42, F1 females 
exposed to 5 mg/kg had significantly increased 
liver:body weight ratios and significant reduc-
tions in total and adjusted body weight, but 
all three parameters were similar to controls 
by 9 weeks of age (PND63). Chronic 5 ppb 
PFOA exposure in drinking water did not 
affect the liver:body weight ratio in F1 off-
spring. In contrast, develop  mental mam-
mary scores of F1 offspring were significantly 
reduced among all treatment groups (includ-
ing 5 ppb in water) until at least 9 weeks of 
age (PND63; Table 2, Figure 1), suggesting 
that delayed mammary gland develop  ment is 
a more sensitive and persistent end point than 
is hepatomegaly.
F1 dams and F2 offspring. We did not 
observe maternal toxicity in F1 dams with 
develop  mental or chronic low-level PFOA 
exposures. Interestingly, the number of uterine 
implants was significantly reduced among 
F1 dams develop  mentally exposed to 5 mg/
kg, resulting in litters with significantly fewer 
offspring (Table 3). As previously described, 
post  natal survival of 5 mg/kg F1 females was 
significantly decreased; however, we observed 
no effect on this end point with respect to 
post  natal survival of F2 offspring. This suggests 
that both F2 thrifti  ness—specifically referring 
to the ability to suckle with sufficient vigor 
and frequency, so as to yield nourish  ment—
and F1 lactational competency were sufficient 
to support litters.
In the lactational challenge on PND10, 
neither milk volume nor timed nursing behav-
ior was significantly different from controls 
with gestational (P0) or chronic, low-level 
PFOA exposure of the F1 dams (Table 3). 
Although we noted large differences in mean 
values (i.e., one-third reduction in milk trans-
ferred to offspring as meas  ured by litter weight 
and an 84-sec longer time to suckling in the 
1-mg/kg + 5 ppb PFOA exposure group 
compared with controls), high variability in 
these responses limited the power to detect a 
significant difference. Nevertheless, F1 lacta-
tional morphology was significantly compro-
mised among all treatment groups at PND10 
(Table 3, Figure 2). By PND22, most mor-
phological delays were no longer evident, and 
only F1 dams with the highest develop  mental 
exposure (i.e., 5 mg/kg PFOA) still exhibited 
morphology that was significantly different 
from controls, with little evidence of normal 
regression. Consistent with this, we observed 
productive spherical alveoli in the 5 mg/kg 
group, in contrast with the regressing alveoli 
and apoptotic bodies observed in controls. 
Of note, at the time F1 dams became preg-
nant and under  went lactational differentia-
tion, their virgin siblings still exhibited stunted 
mammary gland develop  ment in all exposure 
groups compared with controls (PND63; 
Table 2, Figure 1).
Despite striking morphological abnormal-
ities in the lactating glands of PFOA-exposed 
F1 dams on PND10, we found no clear evi-
dence of diminished nutritional support 
provided by these dams based on F2 body 
weights (Table 4). These data suggest that 
nursing behavior of the neonates may have 
changed (i.e., increased number of nursing 
events per day or longer nursing per event) 
to compensate for the decreased potential in 
milk production by the F1 dam, but we did 
not evaluate these end points in this study. 
Adjusted body weights and liver:body weight 
ratios did not demon  strate clear differences by 
treatment group in the F2 offspring (Table 4).
Unlike F1 females, develop  mental mam-
mary gland scores in F2 females did not differ 
in association with maternal exposure; how-
ever, control F2 females exhibited unusually 
low mammary gland scores at PND10 and 
PND22, which might have reduced the sta-
tistical ability to detect effects in other treat-
ment groups at these time points (Table 4). 
At PND22, scores were consistent with 
develop  mental delays in all treatment groups 
relative to controls, but contrasts were not sta-
tistically significant. By PND42, both groups 
with chronic drinking-water exposures (con-
trol + 5 ppb PFOA, 1 mg/kg + 5 ppb PFOA) 
displayed significantly reduced gland develop-
ment relative to controls (Table 4) that was 
characterized by an excess of terminal end 
Table 3. F1 maternal indices (mean ± SE; n = 4–10).
Maternal index Control
Control + 
5 ppb PFOA 1 mg/kg
1 mg/kg + 
5 ppb PFOA 5 mg/kg
Implants (no. per live litter) 14.9 ± 0.4 14.6 ± 0.5 14.1 ± 0.4 13.4 ± 0.9 12.3 ± 0.2*
Live fetuses (no. per live litter) 13.6 ± 0.6 13.1 ± 0.6 12.8 ± 0.6 12.1 ± 0.9 12.0 ± 0.3*
Prenatal loss (% per live litter) 8.6 ± 2.5 9.8 ± 3.2 10.0 ± 3.2 6.7 ± 2.5 2.7 ± 1.4
Postnatal survival (% per live litter) 100 ± 0.0 100 ± 0.0 98.1 ± 1.4 97.9 ± 1.5 100 ± 0.0
Lactational challenge
Milk produced in 30 min (g) 2.10 ± 0.20 1.80 ± 0.35 2.08 ± 0.25 1.40 ± 0.44 1.73 ± 0.51
Time to initiate (sec) 267 ± 38 384 ± 55 307 ± 114 351 ± 86 279 ± 30
Mammary gland score (1–4 scale)
PND10 4.0 ± 0.0 2.8 ± 0.5* 2.5 ± 0.2* 2.0 ± 0.2* 2.5 ± 0.2*
PND22 2.1 ± 0.3 2.2 ± 0.2 1.9 ± 0.4 1.5 ± 0.2* 3.2 ± 0.3*
*p < 0.05 compared with control. 
Figure 2. Histological sections of lactating mammary glands from F1 dams. Glands pictured illustrate morphology representative of respective treatments at given 
times (n = 4 dams/treatment/time point). Arrows indicate presence of alveoli. Bars = 100 μm. 
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buds (TEBs) (Figure 3). Furthermore, mam-
mary gland scores for the F2 offspring of ges-
tationally exposed F1 females in the 5 mg/kg 
group were generally consistent with delayed 
differentiation (Table 4), with histological evi-
dence of postponed lobule formation (arrows 
in Figure 3). We frequently observed a more 
sparse appearance in F2 mammary tissue from 
these three groups (data not shown), resulting 
from delayed ductal outgrowth and persis-
tence of TEBs in adults (arrows in Figure 3).
Water consumption. We calculated aver-
age daily PFOA intake for the two groups 
receiving chronic drinking-water exposures 
from measurements of weekly water con-
sumption [see Supplemental Material, 
Figure 2 (doi:10.1289/ehp.1002741)]. We 
found no difference in water intake between 
groups (as a function of P0 treatment), and 
daily estimated PFOA intake for drinking-
water groups ranged from approximately 50 to 
100 ng, excepting anticipated changes in water 
intake depending on life stage (i.e., increased 
intake during lactation, lower intake in early 
life; see Supplemental Material, Table 1 and 
Supplemental Material, Figure 2).
Serum PFOA analyses. In F1 offspring 
at 9 weeks of age (PND63; Table 5), serum 
PFOA concentrations in the 5 mg/kg group 
were only an order of magnitude greater than 
the levels exhibited in the chronic drinking 
water + 5 ppb PFOA exposure-only group. 
When F1 dams (then 13 weeks of age) 
were weaning their litters (F2 at PND22; 
Table 5), serum PFOA concentrations in the 
F2 drinking-water exposure groups had sur-
passed those of the F2 offspring of F1 dams 
Table 4. F2 developmental indices (mean ± SE; n = 4–10).
Developmental index Control
Control + 
5 ppb PFOA 1 mg/kg
1 mg/kg + 
5 ppb PFOA 5 mg/kg
Body weight (g)
PND1 1.71 ± 0.03 1.61 ± 0.03* 1.63 ± 0.05 1.68 ± 0.05 1.65 ± 0.04
PND3 2.27 ± 0.05 2.22 ± 0.05 2.25 ± 0.09 2.30 ± 0.09 2.22 ± 0.06
PND5 3.24 ± 0.07 3.35 ± 0.10 3.38 ± 0.11 3.42 ± 0.15 3.34 ± 0.09
PND10 5.69 ± 0.22 5.83 ± 0.23 6.00 ± 0.19 5.96 ± 0.18 5.87 ± 0.20
PND14 6.26 ± 0.06 6.34 ± 0.05 7.30 ± 0.25* 7.54 ± 0.33 6.85 ± 0.26
PND17 6.64 ± 0.13 7.05 ± 0.06 8.15 ± 0.31* 8.19 ± 0.39 7.42 ± 0.37
PND22 10.80 ± 0.28 11.41 ± 0.26 13.00 ± 0.50* 13.29 ± 0.61 11.60 ± 0.54
Liver:body weight ratio (×100%)
PND10 2.94 ± 0.15 2.94 ± 0.12 3.08 ± 0.14 2.73 ± 0.14 2.91 ± 0.09
PND22 5.43 ± 0.14 5.25 ± 0.25 5.10 ± 0.21 5.18 ± 0.23 5.11 ± 0.15
PND42 5.43 ± 0.13 5.47 ± 0.10 5.78 ± 0.12 5.36 ± 0.19 5.63 ± 0.21
PND63 5.28 ± 0.25 5.13 ± 0.19 5.05 ± 0.11 5.10 ± 0.15 4.79 ± 0.25
Body weight excluding liver weight (g)
PND10 6.20 ± 0.18 6.15 ± 0.20 6.16 ± 0.14 5.72 ± 0.29 6.44 ± 0.36
PND22 9.75 ± 0.58 10.10 ± 0.18 10.58 ± 0.54 11.29 ± 0.73 10.41 ± 0.78
PND42 22.28 ± 0.79 24.07 ± 0.32 24.12 ± 0.68 25.78 ± 0.55* 24.12 ± 0.51
PND63 27.41 ± 0.76 27.59 ± 1.22 25.98 ± 1.29 28.83 ± 0.90 29.66 ± 2.10
Mammary gland score (1–4 scale)
PND10 2.8 ± 0.3 3.0 ± 0.2 1.9 ± 0.3 2.6 ± 0.2 2.0 ± 0.2
PND22 3.1 ± 0.4 1.9 ± 0.3 2.3 ± 0.1 2.3 ± 0.2 2.0 ± 0.2
PND42 3.5 ± 0.2 2.5 ± 0.4* 3.4 ± 0.2 2.4 ± 0.2*# 3.3 ± 0.4
PND63 3.4 ± 0.2 3.5 ± 0.2 2.4 ± 0.2* 2.6 ± 0.5 2.6 ± 0.4
*p < 0.05 compared with control. #p < 0.05 compared with 1 mg/kg. 
Figure 3. F2 female mammary gland development. Mammary whole-mounts illustrate morphology representative of respective treatment groups at PNDs 10, 22, 
42, and 63 (n = 4–5 females/treatment/age). Arrows indicate remaining TEBs. Bars = 500 μm for PND10, 1,000 μm for PND22, and 2,000 μm for PND42 and PND63. 
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develop  mentally exposed to 1 and 5 mg/kg   
PFOA during their gestation. The con-
trol + 5 ppb PFOA group was particularly 
interesting, because averaged over their life-
times (PNDs 22, 42, and 63, and ~ PND91 
for F1 dams, means averaged for each respec-
tive generation), the F1 and F2 generations 
exhibited nearly identical average serum PFOA 
concentrations, 59.5 and 50.8 ng/mL, respec-
tively. Furthermore, because the final serum 
measurement taken on the F1 generation was 
at 13 weeks post  natally (~ PND91), compared 
with only 9 weeks for the F2 generation, the 
lifetime average may have been skewed slightly 
higher for the F1 generation. Serum PFOA 
concentrations did not differ significantly at 
any time point between the two drinking-
water treatment groups in the F2 generation.
Discussion
Our prior studies identified morphologi-
cal delays in mammary gland develop  ment 
that resulted from gestational PFOA exposure 
(White et al. 2007, 2009), but we did not pre-
viously determine whether such morphological 
effects persisted and were associated with func-
tional consequences, nor did we evaluate the 
effects of low-level, chronic exposures, simi-
lar to non  occupational exposures in humans. 
In the present study, we found evidence that 
the previously reported effects on F1 offspring 
mammary develop  ment—resulting from treat-
ment of P0 dams with 1 or 5 mg/kg PFOA 
during pregnancy—did persist and that these 
histo  pathological diminish  ments in the devel-
oping gland translated to altered lactational 
morphology, when F1 females were bred and 
challenged to lactationally support F2 litters. 
However, these effects were not associated with 
an overt reduction in the nutritional support 
provided by the F1 dam, because F2 offspring 
demon  strated normal post  natal survival and 
weight gain. Among F1 females that received 
only chronic low-level 5 ppb PFOA exposure, 
we also observed comparable and significant 
diminishments in develop  mental morphology 
between PND22 and PND63, as well as in 
later, adult lactational morphology at the peak 
of lactation, suggesting a far greater sensitivity 
of the tissue than previously identified. F2 off-
spring of these F1 dams with only chronic low-
dose exposures also displayed a trend toward 
delayed develop  ment and exhibited signifi-
cantly stunted morphology at PND42.
The degree to which these persistent altera-
tions in F1 mammary gland morphology are 
associated with functional consequences is dif-
ficult to determine because impaired weight 
gain in F2 offspring was the only rele  vant end 
point assessed. The morphological effects of 
PFOA exposure in F1 mammary glands did 
not translate to significant decreases in growth 
and survival of F2 litters, as opposed to the case 
with F1 offspring of P0 dams. Nonetheless, an 
increase in the thriftiness of offspring from the 
F1 to F2 generations or an increase in F2 nurs-
ing frequency could have masked effects on 
milk production in affected lactating F1 glands.
These data suggest that chronic develop-
mental exposure to environmentally relevant 
levels of PFOA may not interfere with lacta-
tion per se, but may reduce the number and 
density of alveoli available to produce milk and 
increase latency to peak milk output, delay-
ing offspring maturation as seen in our pre-
vious work (White et al. 2007). In the case 
of humans, where viable alternatives to breast 
milk are available, low-level functional effects 
on lactation that cause even a short delay in 
substantial milk output might result in formula 
feeding instead of breast-feeding, despite the 
established health benefits of breast-feeding. In 
mammalian wildlife species, critically reliant 
upon lactation to raise their offspring, respon-
siveness of the gland to PFOA might lead to 
delays in milk production, resulting in mal-
nourishment or possibly starvation of offspring, 
in a manner similar to the effects of polychlori-
nated biphenyls on wild mink reproduction in 
the past (Aulerich and Ringer 1977).
Chronic, low-dose PFOA exposure 
in drinking water at human-relevant levels 
(5 ppb) delayed mammary gland develop-
ment in F1 offspring. This exposure yielded 
serum PFOA levels that ranged between 
50 and 100 ng/mL after approximately 
6 weeks (Table 5; lifetime averages: F1 females, 
59.5 ng/mL; F2 females, 50.8 ng/mL; data not 
shown). If these approximate serum concentra-
tion ranges represent those of an animal reach-
ing a steady-state burden, it should be noted 
that they are approximately an order of magni-
tude lower than that seen in some chronically 
exposed human populations. For example, 
communities exposed to 3.55 ppb PFOA in 
municipal supply drinking water exhibited 
mean serum PFOA concentrations of 423 ng/
mL (Emmett et al. 2006), compared with 
the national average of 3.9 ng/mL (Calafat 
et al. 2007). Although it is understood that 
the pharmaco  kinetics of PFOA in the mouse 
differ from those in the human—the half-life 
being approximately 17 days in the mouse and 
3.8 years in the human (Calafat et al. 2007; 
Lou et al. 2009)—it remains dis  concerting 
that the effective circulating dose sufficient to 
yield histopathological changes in the mouse 
mammary gland is approximately an order of 
magnitude lower than the mean serum con-
centration in certain human populations.
These low serum concentrations were associ-
ated with alterations in mouse mammary gland 
morphology in three generations, although we 
could not separate the effects of post  gestational 
chronic exposure in each generation from gesta-
tional exposure in some instances, so the effects 
observed in these treatment groups were not 
necessarily trans  generationally transmitted. 
Because humans with exposures under simi-
lar conditions (contaminated drinking water) 
exhibit higher circulating serum concentrations 
of PFOA, by an order of magnitude—and 
approximately two orders of magnitude above 
the concentration of PFOA in their exposure 
source—the data presented here may actually 
under  represent human-relevant exposure con-
ditions with respect to internal circulating dose. 
However, it is not known whether effects of 
PFOA on the mouse mammary gland translate 
to effects in humans; research is on  going to 
discern a mammary-specific mode of action for 
PFOA and to determine its relevance to human 
breast health.
Conclusion
Our studies identified a gestational expo-
sure lowest observable adverse   effect level 
(LOAEL) of 1 mg/kg PFOA for altered lac-
tational morphology in treated P0 dams and 
altered mammary gland develop  ment in their 
F1 offspring. Additionally, our use of a non-
traditional treatment regimen using low-dose 
continual exposure has generated data that 
will allow others to calculate a lower chronic 
exposure LOAEL or benchmark dose.
Delays in mammary epithelial growth in 
F1 females develop  mentally exposed to PFOA 
reported in this study and others (White et al. 
2007, 2009) translated to histopathological 
changes in subsequent lactational morphol-
ogy. However, this did not result in func-
tional deficits in lactation when F2 offspring 
growth and survival were used as proxy meas-
ures of nutritional support. We observed 
sparse branching morphology and delayed 
differentiation in three generations of CD-1 
Table 5. Serum PFOA concentrations (ng/mL) over three generations (mean ± SE).
Generation/age Control
Control + 
5 ppb PFOA 1 mg/kg
1 mg/kg + 
5 ppb PFOA 5 mg/kg
P0 dams at weaning (PND22) 4.0 ± 0.3 74.8 ± 11.3 6658.0 ± 650.5 4772.0 ± 282.4 26980.0 ± 1288.2
F1 pups
PND22 0.6 ± 0.3 21.3 ± 2.1 2443.8 ± 256.4 2743.8 ± 129.4 10045 ± 1125.6
PND42 1.4 ± 0.4 48.9 ± 4.7 609.5 ± 72.2 558.0 ± 55.8 1581.0 ± 245.1
PND63 3.1 ± 0.2 66.2 ± 4.1 210.7 ± 21.9 187.0 ± 24.1 760.3 ± 188.3
F1 dams at weaning (PND22) 2.0 ± 0.6 86.9 ± 14.5 9.3 ± 2.6 173.3 ± 36.4 18.7 ± 5.2
F2 pups
PND22 0.4 ± 0.0 26.6 ± 2.4 4.6 ± 1.2 28.5 ± 3.7 7.8 ± 1.9
PND42 0.7 ± 0.3 57.4 ± 2.9 0.4 ± 0.0 72.8 ± 5.8 0.4 ± 0.0
PND63 1.1 ± 0.4 68.5 ± 9.4 1.1 ± 0.5 69.2 ± 4.3 1.2 ± 0.5White et al.
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mice, but the global scoring method did not 
indicate consistent differences from controls 
across F2 time points.
Although the chronic low-dose PFOA 
supplied in drinking water in these studies and 
similar concentrations reported in municipal 
drinking-water supplies near fluoro  chemical 
plants are not representative of drinking- 
water supplies in the United States in general, 
PFOA is not regularly moni  tored in drink-
ing water, so national averages cannot be well 
estimated. It is concerning, however, that the 
chronic low dose employed here was sufficient 
to produce changes in the develop  ment of 
the mouse mammary gland; similar develop-
mental changes are physiologically possible in 
girls but would likely not be realized until they 
enter puberty or attempt lactation. Therefore, 
if human exposures in distinct populations are 
approximating those provided in this study, 
concerns over human breast health and lacta-
tional competency are justified.
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